

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb40451</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Designing and Development of a Tandem Bivalent Nanobody against VEGF165</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Khodabakhsh</surname><given-names>Farnaz</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Salimian</surname><given-names>Morteza</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ziaee</surname><given-names>Pardis</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kazemi-Lomedasht</surname><given-names>Fatemeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Behdani</surname><given-names>Mahdi</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ahangari Cohan</surname><given-names>Reza</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>13</volume>
      <issue>2</issue>
      <fpage>58</fpage>
      <lpage>64</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>8</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>11</month>
          <year>2020</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Background:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; Inhibition of angiogenesis using monoclonal antibodies is an effective strategy in cancer therapy. However, they could not penetrate sufficiently into solid tumors. Antibody fragments have solved this issue. However, they suffer from short in vivo half-life. In the current study, a tandem bivalent strategy was used to enhance the pharmacokinetic parameters of an anti-VEGF165 nanobody.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Methods:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; Homology modeling and MD simulation were used to check the stability of protein. The cDNA was cloned into pHEN6C vector and the expression was investigated in WK6 &lt;em&gt;Escherichia coli&lt;/em&gt; (&lt;em&gt;E. coli)&lt;/em&gt; cells by SDS-PAGE and western blot. After purification, the size distribution of tandem bivalent nanobody was investigated by dynamic light scattering. Moreover, &lt;em&gt;in vitro&lt;/em&gt; antiproliferative activity and pharmacokinetic study were studied in HUVECs and Balb/c mice, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Results:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; RMSD analysis revealed the tandem bivalent nanobody had good structural stability after 50 &lt;em&gt;ns&lt;/em&gt; of simulation. A hinge region of llama IgG2 was used to fuse the domains. The expression was induced by 1 &lt;em&gt;mM&lt;/em&gt; IPTG at 25&lt;em&gt;&amp;deg;C&lt;/em&gt; for overnight. A 30 &lt;em&gt;kDa&lt;/em&gt; band in 12% polyacrylamide gel and nitrocellulose paper has confirmed the expression. The protein was successfully purified using metal affinity chromatography. MTT assay revealed there is no significant difference between the antiproliferative activity of tandem bivalent nanobody and the native protein. The hydrodynamic radius and terminal half-life of tandem bivalent nanobody increased approximately 2-fold by multivalency compared to the native protein.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Conclusion:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; Our data revealed that the physicochemical as well as &lt;em&gt;in vivo&lt;/em&gt; pharmacokinetic parameters of tandem bivalent nanobody was significantly improved.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
